Biden Proposes That Insurers Cover Over-the-Counter Birth Control
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer
Findings seen in combination with chemotherapy following surgery in patients with curative intent
Measures of Social Support Linked to Cancer Screening
Those who report never/rarely versus always having social support may have lowest odds of screening
Breast Cancer Risk Elevated With Levonorgestrel-Releasing Intrauterine System Use
Excess risk of 14 per 10,000 women seen with zero to five years of LNG-IUS use
Excess Adiposity Plays Role in Postmenopausal HR-Positive Breast Cancer
Estimated burden of 19.9 percent reported for body mass index and 41.9 percent for Clínica Universidad de Navarra-Body Adiposity Estimator
In Utero Exposure to COVID-19 Not Tied to Later Neurodevelopmental Issues
Findings seen for offspring evaluated through 24 months postpartum
IOTA ADNEX at 10 Percent Has Higher Sensitivity for Ovarian Cancer
Sensitivity higher, but some loss seen in specificity, when compared with Risk of Malignancy 1 index at threshold of 250
FDA Approves Itovebi for Locally Advanced, Metastatic Breast Cancer
Approval is for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative disease
Industry Payments Common for Physician Peer Reviewers of Top Journals
Peer reviewers in this study received $64.18 million in general payments between 2020 and 2022
